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Available online 12 February 2016Background: Individual functional system scores (FSS) of the Expanded Disability Status Scale (EDSS) play a cen-
tral role in determining the overall EDSS score in patients with early-stagemultiple sclerosis (MS). Alemtuzumab
treatment improves preexisting disability for many patients; however, it is unknown whether improvement is
speciﬁc to certain functional systems.
Objective:We assessed the effect of alemtuzumab on individual FSS of the EDSS.
Methods: CAMMS223 was a 36-month, rater-blinded, phase 2 trial; treatment-naive patients with active
relapsing-remitting MS, EDSS ≤3, and symptom onset within 3 years were randomized to annual courses of
alemtuzumab or subcutaneous interferon beta-1a (SC IFNB-1a) 44 μg three times weekly.
Results:Alemtuzumab-treatedpatients had improvedoutcomes versus SC IFNB-1apatients onmost FSS atMonth
36; the greatest effect occurred for sensory, pyramidal, and cerebellar FSS. Among patients who experienced 6-
month sustained accumulation of disability, clinical worsening occurred most frequently in the brainstem and
sensory systems. For patients with 6-month sustained reduction in preexisting disability, pyramidal and sensory
systems contributed most frequently to clinical improvement.
Conclusions: Alemtuzumab demonstrated a broad treatment effect in improving preexisting disability. These
ﬁndings may inﬂuence treatment decisions in patients with early, active relapsing-remitting MS displaying
neurological deﬁcits. ClinicalTrials.gov Identiﬁer NCT00050778.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Multiple sclerosis1. Introduction
Alemtuzumab (LEMTRADA™) is a humanized monoclonal antibody
that selectively targets CD52 to deplete circulating T and B lymphocytes,
thought to be criticalmediators ofmultiple sclerosis (MS) inﬂammatory
processes [1,2]. After lymphocyte depletion, a distinctive pattern of T-
and B-cell repopulation begins within weeks, leading to a rebalanced
immune system [3,4]. Alemtuzumab is approved in many countries as
treatment for adult patients with relapsing-remitting MS (RRMS) who
also meet country-speciﬁc selection criteria. Alemtuzumab has been
evaluated in one 3-year phase 2 trial (CAMMS223, ClinicalTrials.gov
identiﬁer NCT00050778) [5] and two 2-year phase 3 studies (Compari-
son of Alemtuzumab and Rebif® Efﬁcacy in Multiple Sclerosis I [CARE-
MS I, NCT00530348] and CARE-MS II [NCT00548405]) [6,7].
Alemtuzumab signiﬁcantly reduced the risk of relapse and showedxas, Central Texas Neurology
d Rock, TX 78681, USA.
nnmd@gmail.com (D. Wynn),
genzyme.com (D.H. Margolin).
. This is an open access article undersigniﬁcant beneﬁt on many radiological outcomes versus subcutaneous
interferon beta-1a (SC IFNB-1a, Rebif®; EMDSerono, Inc., Rockland,MA)
in active RRMS patients who were treatment-naive (CAMMS233 and
CARE-MS I) [5,6] or who had inadequate efﬁcacy response, deﬁned as
at least one relapse, to prior therapy (CARE-MS II) [7]. Safety ﬁndings
with alemtuzumab were consistent across trials, with the most com-
mon adverse events being infusion-associated reactions; other notable
adverse events were infections and autoimmune adverse events [5–8].
Disability in patients with MS is commonly assessed using the
Expanded Disability Status Scale (EDSS), which is a 10-point scale
with 0.5-point steps based on seven functional systems [9]. These func-
tional systems measure different aspects of disability, i.e., impairments
in bowel/bladder, brainstem, cerebellar, cerebral, pyramidal, sensory,
and visual functioning. In the early stages of MS, individual functional
systems of the EDSS play a greater role than ambulatory impairment
in determining the overall EDSS score, and patients are more likely to
experience deﬁcits in the functional systems of pyramidal, cerebellar,
brainstem, and sensory than in the systems of visual, bowel/bladder,
and cerebral [10].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ability (deﬁned as EDSS score ≤ 3), as is the case withmanyMS patients
in clinical trials [11–14]. In this trial, the rate of sustained accumulation
of disability (SAD; deﬁned as an increase from baseline in EDSS score of
≥1.0 [≥1.5 in patients with a baseline EDSS score of 0]) conﬁrmed over
6 months was reduced by 71% with alemtuzumab versus SC IFNB-1a
(p b 0.001). Disability measured by mean EDSS score over time also de-
creased signiﬁcantly with alemtuzumab, but increasedwith SC IFNB-1a.
Furthermore, sustained reduction in preexisting disability (SRD; a de-
crease from baseline by ≥1 EDSS point in patients with baseline EDSS
scores ≥ 2.0) conﬁrmed over 6 months was signiﬁcantly more likely to
be observed in alemtuzumab patients [8]. More recently, similar results
for these disability endpoints were reported for patients enrolled in
CARE-MS II [7].
In the present analysis of CAMMS223, we examined the treatment
effect of alemtuzumab compared with SC IFNB-1a on each of the indi-
vidual EDSS functional systems to determine if alemtuzumab's beneﬁ-
cial treatment effect is broadly based or speciﬁc to certain functional
systems. Additionally, we examined the relationship between overall
EDSS and the functional systems to understand which systems contrib-
ute to SAD and to SRD among alemtuzumab-treated patients.
2. Methods
Detailed methods for CAMMS223 have previously been published
[5]; a brief summary is provided here.
2.1. Patients
Treatment-naive patients with RRMS with EDSS scores of ≤3.0, MS
symptom onset within 3 years, at least two relapses in the previous
2 years, and evidence of at least one gadolinium-enhancing lesion on
any of up to four monthly screening MRI scans were randomized to
the study. Due to a misdiagnosis of MS, one patient was not included
in the efﬁcacy analyses. Ethics board approvals were obtained from all
sites, and all patients provided written informed consent.
2.2. Study design
CAMMS223 was a 3-year, rater-blinded, active-controlled, head-to-
head, phase 2 trial. Patients were randomly allocated in a 1:1 ratio to re-
ceive alemtuzumab 12 mg or SC IFNB-1a (44 μg three times per week).
Other patients were randomized to receive alemtuzumab 24 mg. How-
ever, since the 24-mg dose level is not approved for use in treatment of
MS in any jurisdiction and is no longer being studied, and given the ro-
bust effects observed at the 12-mg dose, analyses of the 24-mg group
are omitted from this report. Alemtuzumab was administered via intra-
venous infusions on 5 consecutive days at baseline and on 3 consecutive
days 12months and 24months later (the latter coursewas optional and
at the discretion of the treating physician if the CD4+ T-cell count was
≥100 × 106 cells/L). In September 2005, alemtuzumab dosing within
the trial was suspended after immune thrombocytopenia developed in
three patients (including the fatal index case). All safety and efﬁcacy as-
sessments proceeded as planned, and patients in the SC IFNB-1a group
continued to receive medication [5]. The alemtuzumab dosing suspen-
sion was lifted in April 2008 [15]. As a result of the suspension, 75% of
patients were precluded from receiving the optional third course of
alemtuzumab at Month 24.
2.3. Study outcomes
The results of this study represent Class I evidence due to several
characteristics of the study design. Those assessments in the study
pertaining to the key efﬁcacy endpoints (e.g., EDSS for disability and
relapse) used masked raters. The study was randomized to ensurethat the baseline characteristics were comparable between treatment
arms.
2.4. Disability assessment
The EDSS score was assessed at baseline and quarterly using the
“Neurostatus” training and scoring system [16] by a neurologist blinded
to treatment arms. The functional systems assessed in the present anal-
ysis were bowel/bladder, brainstem, cerebellar, cerebral, pyramidal,
sensory, and visual.
2.5. Statistical analysis
Summary statistics of observed values and change from baseline
were calculated for each functional system at each time point. For
functional system scores (FSS) that included a letter for subclass iden-
tiﬁcation (such as 1X, 2A, and 3B), only the numeric portion was used
for the statistical analysis. A signiﬁcance level of 0.05 was used for
these post hoc analyses, and no adjustment was made for multiple hy-
pothesis testing. All FSS were evaluated equally throughout this analy-
sis. All statistical tests were two-sided. Change from baseline for each
functional system was categorized as improved (decreased FSS of at
least 1.0 point), no change (stable FSS ±0.5 point), or worsened (in-
creased FSS of at least 1.0 point). The overall treatment effect across
all time points through Month 36 was tested with a repeated measures
proportional odds model. The above analysis was also conducted using
a subset of patients who had received only two annual courses of
alemtuzumab.
Kaplan-Meier and Cox proportional hazardsmodel analyses for each
functional system were conducted for time to sustained (≥6 months)
clinical worsening of functional system and time to sustained clinical
improvement of functional system. Clinical worsening was deﬁned as
an on-treatment FSS increase of ≥2.0 points for patients with a baseline
score ≤ 1.0, or any increase in score from a baseline FSS of ≥2.0 points.
Clinical improvement was deﬁned as a ≥1.0-point decrease in FSS for
the subset of patients with baseline FSS ≥1.0. Analyses of visual and
bowel/bladder functional systems used actual, not converted scores.
Spearman correlation coefﬁcients were used to compare FSS changes
from baseline at Months 6 and 36. For patients with 6-month SAD in
EDSS, the number of patients with worsening in each functional system
at the time of SADwas counted. For patients with 6-month SRD in EDSS,
the number of patients with improvement in each functional system at
the time of SRD was counted.
3. Results
3.1. Patients
Complete demographic and baseline clinical characteristics and pa-
tient disposition have been previously reported [5]. Baseline character-
istics were well-balanced between the SC IFNB-1a (N = 111) and
alemtuzumab 12-mg (N = 112) treatment groups. The mean age of
the total population was 32.3 years, 64.3% were female, and 90.1%
were Caucasian. The mean EDSS score was 1.9, 94.9% of patients had
an EDSS score ≥ 1, and the mean time since ﬁrst relapse was 1.5 years.
Of the patients randomized to receive alemtuzumab 12 mg, 6 patients
received only one course, 78 received two courses, and 24
received three courses during the core 36-month study.
3.2. Functional systems
All FSS were balanced between treatment groups at baseline. With-
in the alemtuzumab treatment group, the largest mean reductions
from baseline to Month 36 occurred in the sensory (−0.28 points), py-
ramidal (−0.17 points), and cerebellar FSS (−0.15 points). Compared
with patients receiving SC IFNB-1a, patients in the alemtuzumab group
ig. 1.Mean changes from baseline for the Expanded Disability Status Scale (EDSS) and functional system scores. Abbreviations: IFNB-1a, interferon beta-1a; SC, subcutaneous. *p b 0.05,
lemtuzumab 12 mg vs SC IFNB-1a.
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Fig. 2. Odds ratios (ORs) for Expanded Disability Status Scale (EDSS) and functional systems (FS) score improvements over 36 months, alemtuzumab 12 mg vs subcutaneous interferon
beta-1a (SC IFNB-1a) 44 μg: (A) overall patient cohort and (B) patients receiving only two alemtuzumab 12-mg courses.
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reductions from baseline through Month 36, with the sensory, pyrami-
dal, cerebellar, and brainstem FSS showing the greatest treatment ef-
fect (Fig. 1). Changes from baseline versus SC IFNB-1a were
statistically signiﬁcant (p b 0.05) in the alemtuzumab treatment
group for the brainstem, pyramidal, and cerebellar FSS for at least
half of the time points assessed. Repeated measures proportional
odds analyses through Month 36 indicated that treatment with
alemtuzumab led to a consistently better outcome on each functional
system compared with SC IFNB-1a (Fig. 2). For the alemtuzumab
group, the effect was statistically signiﬁcant versus SC IFNB-1a for
the sensory, pyramidal, brainstem, and bowel/bladder functional sys-
tems. Although numerically favorable for alemtuzumab, results for
the cerebral, cerebellar, and visual functional systems did not achieve
statistical signiﬁcance (Fig. 2A). Results were similar to the above
when comparing FSS changes for alemtuzumab-treated patients who
received only two courses of alemtuzumab with those for SC IFNB-1a
patients (Fig. 2B).
Patients treated with alemtuzumab were also less likely to experi-
ence sustained clinical worsening of FSS and more likely to experience
sustained clinical improvement of FSS in most of the functional systems
compared with patients treated with SC IFNB-1a. In patients treated
with alemtuzumab, the beneﬁcial treatment effect versus SC IFNB-1awas signiﬁcant for sustained clinical worsening in the pyramidal func-
tional system, and for sustained clinical improvement in the pyramidal
and sensory functional systems (Table 1).
3.3. Relationship of functional system changes to changes in EDSS scores in
alemtuzumab-treated patients
The relationship between functional systems and sustained changes
in EDSSwas examined. Among the 18 alemtuzumabpatientswho expe-
rienced 6-month SAD in EDSS, the associated worsening occurred most
often in the brainstem and sensory functional systems (both 38.9% of
patients who experienced SAD) and least often in the visual functional
system (5.6%) (data not shown). For the 66 alemtuzumab patients
with 6-month SRD in EDSS, the pyramidal functional system contribut-
ed most often (53.0% of SRD events) to that clinical improvement,
whereas the bowel/bladder functional system contributed least often
(19.7%) (data not shown).
4. Discussion
The involvement of a greater number of functional systems early
in MS disease predicts the accumulation of future disability [17,18],
so it is important to understand the number and identity of the
192 E.J. Fox et al. / Journal of the Neurological Sciences 363 (2016) 188–194functional systems impacted by disease-modifying therapy to in-
form treatment choices. Although few data exist to describe which
functional systems are most impacted by disease-modifying thera-
pies, evidence from a previous study demonstrated that therapies
with beneﬁts on disability outcomes do not necessarily impact all af-
fected functional systems equally. In that analysis, intramuscular
IFNB-1a was found to have a statistically signiﬁcant positive effect
compared with placebo on scores in the pyramidal system only.
This was despite the observation that the study population had pyra-
midal (37%), cerebellar (38%), and sensory (34%) involvement at
baseline [19].
As previously reported, alemtuzumab treatment led to a signiﬁ-
cant and sustained improvement in preexistingMS-related disability
comparedwith SC IFNB-1a [5,8]. Alemtuzumab's greater suppression
of MS relapse and new brain lesion formation does not fully account
for the differential effect on disability as measured by EDSS [20]. The
present report extends these ﬁndings with the observation that
alemtuzumab's positive effects on disability, as assessed by the over-
all EDSS score, were similarly observed in each of the individual
functional systems. Patients receiving alemtuzumab had a consis-
tently better outcome for all functional systems compared with pa-
tients receiving SC IFNB-1a, with the strongest treatment effectsTable 1
Kaplan-Meier analyses for 6-month sustained clinical worsening and 6-month sustained clinic
Functional system SC IFNB-1a 44 μg
(N= 111)
Alemtu
(N= 1
6-Month sustained clinical worse
Visual
Patients with outcome – n 3 2
KM estimate of event (95% CI) 0.03 (0.010, 0.089) 0.02 (0
Hazard ratio (95% CI) 0.67 (0
Treatment effect – % 33.0
p value 0.6640
Brainstem
Patients with outcome – n 3 4
KM estimate of event (95% CI) 0.04 (0.012, 0.107) 0.05 (0
Hazard ratio (95% CI) 1.21 (0
Treatment effect – % 21.1
p value 0.8022
Pyramidal
Patients with outcome – n 8 1
KM estimate of event (95% CI) 0.09 (0.047, 0.176) 0.01 (0
Hazard ratio (95% CI) 0.12 (0
Treatment effect – % 88.0
p value 0.0457
Cerebellar
Patients with outcome – n 5 4
KM estimate of event (95% CI) 0.06 (0.027, 0.148) 0.04 (0
Hazard ratio (95% CI) 0.68 (0
Treatment effect – % 31.9
p value 0.5679
Sensory
Patients with outcome – n 5 2
KM estimate of event (95% CI) 0.06 (0.025, 0.139) 0.02 (0
Hazard ratio (95% CI) 0.26 (0
Treatment effect – % 74.4
p value 0.1076
Bowel/bladder
Patients with outcome – n 3 1
KM estimate of event (95% CI) 0.03 (0.011, 0.107) 0.01 (0
Hazard ratio (95% CI) 0.34 (0
Treatment effect – % 66.1
p value 0.3496
Cerebral
Patients with outcome – n 3 1
KM estimate of event (95% CI) 0.03 (0.010, 0.092) 0.01 (0
Hazard ratio (95% CI) 0.30 (0
Treatment effect – % 69.9
p value 0.2988
Abbreviations: CI, conﬁdence interval; IFNB-1a, interferon beta-1a; SC, subcutaneous.being observed for the sensory, pyramidal, and cerebellar functional
systems.
These treatment effects were durable, being sustained through
Month 36 even though most patients had last received alemtuzumab
at Month 12. Indeed, results from the subgroup of patients who re-
ceived only two courses of alemtuzumab, and received no therapy
for the ﬁnal 24 months of follow-up, were comparable to those in
the overall alemtuzumab group. Furthermore, similar ﬁndings were re-
ported in an analysis of EDSS FSS in CARE-MS II, in which all
alemtuzumab patients were randomized to receive 2 courses in the
core study [21].
Changes in any FSS can impact the overall EDSS score, by deﬁnition,
but some functional systems are more often involved in MS relapses
and consequently are more likely to change. Furthermore, all FSS
changes may not be equally likely to persist and to lead to sustained
clinical worsening of FS or sustained clinical improvement of FS. In
our study, onset of SAD was most often linked with worsening in the
sensory and brainstem functional systems and least frequently with vi-
sual functional system change. Among patients who experienced SRD,
the pyramidal functional system contributed most frequently to that
clinical improvement, whereas the bowel/bladder functional system
contributed the least. This apparent driving of EDSS changes by moreal improvement for functional systems over 36 months (full analysis set).
zumab 12 mg
12)
SC IFNB-1a 44 μg
(N= 111)
Alemtuzumab 12 mg
(N= 112)
ning 6-Month sustained clinical improvement
24 34
.005, 0.078) 0.26 (0.184, 0.370) 0.33 (0.248, 0.433)
.110, 4.072) 1.35 (0.796, 2.274)
34.5
0.2686
13 23
.017, 0.119) 0.14 (0.081, 0.224) 0.22 (0.151, 0.310)
.270, 5.434) 1.84 (0.930, 3.639)
84.0
0.0799
12 34
.001, 0.068) 0.13 (0.077, 0.225) 0.33 (0.246, 0.428)
.015, 0.960) 2.88 (1.485, 5.583)
187.9
0.0018
17 27
.015, 0.101) 0.18 (0.116, 0.276) 0.26 (0.182, 0.350)
.182, 2.543) 1.68 (0.913, 3.085)
67.8
0.0954
24 38
.005, 0.081) 0.26 (0.181, 0.366) 0.36 (0.277, 0.460)
.048, 1.346) 1.70 (1.016, 2.839)
69.8
0.0433
19 19
.001, 0.064) 0.21 (0.137, 0.308) 0.18 (0.120, 0.271)
.035, 3.268) 0.88 (0.466, 1.668)
11.9
0.6980
15 22
.001, 0.069) 0.16 (0.100, 0.255) 0.21 (0.145, 0.304)
.031, 2.902) 1.44 (0.748, 2.789)
44.4
0.2734
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brainstem FSS, minimizes the likelihood of the EDSS ﬁndings being in-
ﬂuenced by potential bias resulting from patient blinding not being
possible in this study. The relationship between functional systems
and EDSS was similar to that reported by Scott et al., who identiﬁed
the pyramidal and cerebellar functional systems as the systems most
responsive to MS disease-modifying therapy at multiple levels of the
EDSS [19].
The observation that improvements with alemtuzumab over SC
IFNB-1a in our studywere seen across all of the functional systems indi-
cates potential beneﬁts in multiple aspects of patients' quality of life
(QoL). Indeed, our results are consistent with QoL analyses of phase 3
trial data showing improvement in a variety of QoL measures with
alemtuzumab over time, as well as in comparison with SC IFNB-1a
[22]. Furthermore, the particularly strong effects of alemtuzumab on
the pyramidal functional systems in our present study are in agreement
with the observation that the most profound QoL beneﬁts with
alemtuzumab were seen in mobility and other physical components of
the QoL scales assessed [22].
Limitations of this study include themodest degree of change in FSS
that is observed in the early stages of MS (all patients had a baseline
EDSS ≤3 in this study). At a higher baseline EDSS, the contribution of in-
dividual FSS to the overall EDSS score may have been different. Addi-
tionally, differential dropout of patients treated with SC IFNB-1a may
have biased results at later time points in the study. Per protocol, pa-
tients who experienced an SAD event in the study discontinued from
the trial. As more patients treated with SC IFNB-1a had SAD early in
the course of the trial, the discontinuation rate in this treatment arm
was higher than in the alemtuzumab treatment arm. However, this lim-
itation would tend to bias the results against alemtuzumab, since dis-
continuation of SC IFNB-1a patients with SAD removed their
worsening values from the SC IFNB-1a group's mean at subsequent
time points. Thus, our ﬁndingsmay underestimate alemtuzumab's rela-
tive treatment effect, but that would not alter the conclusions of this
study.
In conclusion, alemtuzumab's greater efﬁcacy compared with SC
IFNB-1a, an active comparator, was observed consistently across all
functional systems, indicating a broad treatment effect.Whether neuro-
logical impairments residual from prior MS attacks involvedmotor con-
trol or sensation or sphincter control, they were more likely to improve
with alemtuzumab treatment than with SC IFNB-1a. Since
alemtuzumab's effect was most evident in the functional systems
most often affected and most strongly driving SAD in early RRMS,
these ﬁndings are likely to have clinical relevance.
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